Gilead Sciences has bolstered its position in the ... $225 million upfront plus a $100 million equity investment, and a partnership with Refuge Biotech on a gene editing platform designed to ...

Gilead's HIV portfolio remains dominant but faces Medicare Part D pricing pressure, limiting future growth potential. New ...

Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...

Gilead Sciences sets aside $200 million for a potential settlement over its HIV drug promotional speaker program amid federal ...

FOSTER CITY, Calif. & BALLERUP, Denmark, January 11, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and commerciali ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year.

YANKCOM Partnership purchased a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $28,000. Decker Retirement Planning Inc. purchased a new stake in shares of Gilead ...

Gilead Sciences Background Information (This description ... since the company brought its first therapies to the market. Through global partnerships, Gilead's medicines today reach millions ...

About Gilead HIV Gilead Sciences, Inc. is a biopharmaceutical ... needs of people affected by HIV around the world. Through partnerships, collaborations and charitable giving, the company also ...

Phase 1 Data Indicate Potential for Use of Once-Yearly Lenacapavir for HIV Prevention, with Plans to Launch a Phase 3 Trial in 2H 2025 – ...